{"id":65236,"date":"2026-05-13T23:53:27","date_gmt":"2026-05-13T15:53:27","guid":{"rendered":"https:\/\/flcube.com\/?p=65236"},"modified":"2026-05-13T23:53:27","modified_gmt":"2026-05-13T15:53:27","slug":"eli-lilly-reports-long-term-weight-loss-maintenance-with-foundayo-and-lower-dose-zepbound-in-phase-3-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65236","title":{"rendered":"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced on May 12, 2026, detailed results from two late-phase trials, <strong>SURMOUNT-MAINTAIN<\/strong> and <strong>ATTAIN-MAINTAIN<\/strong>, demonstrating that patients with obesity successfully <strong>maintained long-term weight loss<\/strong> after transitioning from higher doses of injectable incretin therapy to either <strong>Foundayo<\/strong> (oral GLP-1 agonist) or <strong>lower-dose Zepbound<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-overview\">Clinical Trial Results Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Transition Protocol<\/th><th>Weight Regain After 1 Year<\/th><th>Primary Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>ATTAIN-MAINTAIN<\/strong><\/td><td>Switched from Zepbound MTD \u2192 Foundayo (oral)<\/td><td>5.0 kg average regain<\/td><td>Successful weight maintenance with oral therapy<\/td><\/tr><tr><td><strong>SURMOUNT-MAINTAIN<\/strong><\/td><td>Reduced Zepbound dose from MTD \u2192 5 mg<\/td><td>5.6 kg average regain<\/td><td>Effective maintenance with lower-dose injectable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-efficacy-metrics\">Key Efficacy Metrics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Weight loss preservation<\/strong>: Patients maintained <strong>>90% of their initial weight loss<\/strong> achieved during intensive treatment phase<\/li>\n\n\n\n<li><strong>Treatment sustainability<\/strong>: Both oral and lower-dose injectable options provide viable long-term maintenance strategies<\/li>\n\n\n\n<li><strong>Clinical significance<\/strong>: Average weight regain of <strong>5-6 kg<\/strong> represents minimal reversal of substantial initial weight loss<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-comparison\">Drug Profile &amp; Mechanism Comparison<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-zepbound-tirzepatide\">Zepbound (tirzepatide)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Once-weekly dual <strong>GIP\/GLP-1 receptor agonist<\/strong><\/li>\n\n\n\n<li><strong>Administration<\/strong>: Subcutaneous injection<\/li>\n\n\n\n<li><strong>Dosing strategy<\/strong>: Maximum tolerated dose (MTD) for intensive phase, <strong>5 mg for maintenance<\/strong><\/li>\n\n\n\n<li><strong>Market status<\/strong>: Already approved for obesity treatment<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-foundayo-orforglipron\">Foundayo (orforglipron)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Once-daily <strong>oral small molecule GLP-1 receptor agonist<\/strong> (non-peptide)<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral tablet<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Represents <strong>first oral GLP-1 agonist<\/strong> in Lilly&#8217;s obesity portfolio<\/li>\n\n\n\n<li><strong>Development stage<\/strong>: Late-phase clinical evaluation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-therapeutic-implications\">Strategic Therapeutic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatment-paradigm-evolution\">Treatment Paradigm Evolution<\/h3>\n\n\n\n<p>The results support a <strong>two-phase obesity management approach<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Objective<\/th><th>Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>Intensive Weight Loss<\/strong><\/td><td>Maximize weight reduction<\/td><td>Zepbound at maximum tolerated dose<\/td><\/tr><tr><td><strong>Long-term Maintenance<\/strong><\/td><td>Sustain weight loss with improved tolerability<\/td><td>Foundayo (oral) or Zepbound 5 mg (lower-dose injectable)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-patient-centric-benefits\">Patient-Centric Benefits<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral option<\/strong>: Foundayo provides <strong>non-injectable alternative<\/strong> for maintenance therapy<\/li>\n\n\n\n<li><strong>Dose flexibility<\/strong>: Lower-dose Zepbound offers <strong>reduced side effects<\/strong> while maintaining efficacy<\/li>\n\n\n\n<li><strong>Adherence improvement<\/strong>: Both options designed to enhance long-term treatment compliance<\/li>\n\n\n\n<li><strong>Cost optimization<\/strong>: Potential for reduced medication costs with lower maintenance doses<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-obesity-treatment-market-dynamics\">Obesity Treatment Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market expansion<\/strong>: Global obesity therapeutics market projected to exceed <strong>$100 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>GLP-1 dominance<\/strong>: Incretin-based therapies establishing as standard of care for chronic weight management<\/li>\n\n\n\n<li><strong>Oral delivery race<\/strong>: Intense competition among pharmaceutical companies to develop effective oral GLP-1 agonists<\/li>\n\n\n\n<li><strong>Treatment sustainability<\/strong>: Industry focus shifting from maximal weight loss to long-term maintenance strategies<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-lilly-s-portfolio-strategy\">Lilly&#8217;s Portfolio Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Zepbound leadership<\/strong>: Dual GIP\/GLP-1 agonist maintains competitive advantage over single GLP-1 agents<\/li>\n\n\n\n<li><strong>Oral innovation<\/strong>: Foundayo positions Lilly to capture patients preferring non-injectable options<\/li>\n\n\n\n<li><strong>Dosing optimization<\/strong>: Maintenance data supports flexible treatment approaches tailored to patient preferences<\/li>\n\n\n\n<li><strong>Market differentiation<\/strong>: Comprehensive obesity management system combining intensive and maintenance phases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications\">Commercial Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prescribing-patterns\">Prescribing Patterns<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sequential therapy<\/strong>: Physicians likely to adopt intensive-to-maintenance treatment algorithms<\/li>\n\n\n\n<li><strong>Patient retention<\/strong>: Improved long-term adherence could increase treatment duration and revenue<\/li>\n\n\n\n<li><strong>Market segmentation<\/strong>: Oral vs. injectable options address different patient populations and preferences<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pricing-strategy\">Pricing Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Premium pricing<\/strong>: Maintenance therapies likely to command significant pricing given sustained efficacy<\/li>\n\n\n\n<li><strong>Value-based positioning<\/strong>: Demonstrated long-term weight maintenance supports premium reimbursement<\/li>\n\n\n\n<li><strong>Competitive pricing<\/strong>: Oral Foundayo may be priced competitively against other oral metabolic agents<\/li>\n<\/ul>\n\n\n\n<p>The trial results validate Lilly&#8217;s <strong>comprehensive obesity management strategy<\/strong>, offering healthcare providers multiple evidence-based options to sustain meaningful weight loss over the long term while addressing diverse patient preferences and tolerability requirements.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,199,911,86],"class_list":["post-65236","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, demonstrating that patients with obesity successfully maintained long-term weight loss after transitioning from higher doses of injectable incretin therapy to either Foundayo (oral GLP-1 agonist) or lower-dose Zepbound.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65236\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, demonstrating that patients with obesity successfully maintained long-term weight loss after transitioning from higher doses of injectable incretin therapy to either Foundayo (oral GLP-1 agonist) or lower-dose Zepbound.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65236\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T15:53:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65236#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65236\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials\",\"datePublished\":\"2026-05-13T15:53:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65236\"},\"wordCount\":554,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65236#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65236\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65236\",\"name\":\"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T15:53:27+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, demonstrating that patients with obesity successfully maintained long-term weight loss after transitioning from higher doses of injectable incretin therapy to either Foundayo (oral GLP-1 agonist) or lower-dose Zepbound.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65236#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65236\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65236#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, demonstrating that patients with obesity successfully maintained long-term weight loss after transitioning from higher doses of injectable incretin therapy to either Foundayo (oral GLP-1 agonist) or lower-dose Zepbound.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65236","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials","og_description":"Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, demonstrating that patients with obesity successfully maintained long-term weight loss after transitioning from higher doses of injectable incretin therapy to either Foundayo (oral GLP-1 agonist) or lower-dose Zepbound.","og_url":"https:\/\/flcube.com\/?p=65236","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T15:53:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65236#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65236"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials","datePublished":"2026-05-13T15:53:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65236"},"wordCount":554,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Eli Lilly","NYSE: LLY","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65236#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65236","url":"https:\/\/flcube.com\/?p=65236","name":"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T15:53:27+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, demonstrating that patients with obesity successfully maintained long-term weight loss after transitioning from higher doses of injectable incretin therapy to either Foundayo (oral GLP-1 agonist) or lower-dose Zepbound.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65236#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65236"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65236#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65236"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65236\/revisions"}],"predecessor-version":[{"id":65237,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65236\/revisions\/65237"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}